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The issue of the generic versus brand-name drug inter-
changeability is an intensely debated theme historically
focused on whether bioequivalence testing can guarantee
therapeutic eﬃcacy. The controversy is supported by reports
of the lack of therapeutic equivalence between some generic
medicinal products and brand-name drugs, as well as
by a great deal of editorials expressing a negative view
on generic drug substitution. This could be of particular
concern for critical therapeutic categories such as psy-
chotropic, cardiovascular, and metabolic/endocrine drugs as
well as for special subpopulations such as elderly, debili-
tated/psychoneurotic patients, infants and children [1, 2]. To
deal with this issue, large, prospective controlled evaluations
have been proposed, providing information on how current
bioequivalence and pharmacological equivalence translate
into clinical equivalence [3]. In our opinion, however,
although on one hand this strategy could be suitable in
clinical trials to ascertain the “essential similarity” require-
ment in drug substitution—in terms of active ingredient
(amount and type), route of administration, and therapeutic
eﬀectiveness—on the other hand, it might be insuﬃcient in
real practice to support the therapeutic equivalence for the
general population. This could also be due to the possible
inﬂuence of the marketing to patient’s response.
To better explain what we are saying, let us recall what
follows.Ourknowledgeontheplaceboeﬀect,aphenomenon
that has intrigued scientists since 1955 when Henry K.
Beecher published the article “The powerful placebo” [4]
and quantiﬁed the placebo eﬀect [5], has evolved from being
thought of as a nuisance in pharmacological intervention
to the mechanistic aspects of its incontrovertible function.
Two main models of how the placebo—or placebo related
eﬀects—workshavebeenproposed.The“expectancetheory,”
which is essentially based on the patient’s expectation of
clinical beneﬁts occurring in association with the verbal
suggestion that clinical improvement will soon occur; the
“classic conditioning” model foresees that after repeated
associationsbetweenaconditionedstimulus(e.g.,colourand
shape of a pill) and an unconditioned stimulus (e.g., the
active agent in the pill), the ﬁrst stimulus alone may induce a
conditionedresponsesimilartotheoneinducedbytheactive
drug [6].
There is no doubt that, in randomized, double-blind
controlled studies, the contribution of the placebo eﬀect to
therapeutic eﬃcacy is “equally distributed” between patients
receiving the generic product and the ones taking the brand
name with an overall nondiscriminating therapeutic role
between these two patient classes. In this case, identical
medical information and “apparently” identical medica-
ments are, indeed, given. However, in real practice, the
frequent choice of the cheaper drug over the generic drug,
ignoring physician recommendations for the brand name
(contradicting the expectation theory) and/or the total or
partiallackinthegenericproductofconventionalperceptual
characteristics aﬀecting patient expectation (contradicting
the classic conditioning theory), such as preparation form
(e.g., capsule or pill), size, colour, taste, and packaging [7],
allregularlyfoundinthebrandname,maytotallyorpartially
cancel the placebo eﬀect.
This phenomenon is reinforced by commercial feature
changes. The term “generic” evokes a poor product quality
so that, if compared to the term “brand” evoking the gold
standard (like designer clothes), it can subsequently reduce
the placebo contribution to therapeutic eﬃcacy. It is fairly2 Journal of Biomedicine and Biotechnology
signiﬁcant that a recent trial on the placebo responses to
commercial variables showed that the medicines believed
to be less expensive (discounted) proved less eﬀective than
the regular price ones [8]. So, paradoxically, the “conscious”
choice of the generic product because of economic beneﬁts
can “unconsciously” reduce the eﬃcacy of the medical
therapy.
Although approximately 50% of pharmacy prescriptions
in the USA and EU are ﬁlled with generic drugs, resulting
inconsiderablecostsavings,indiscriminateswitchingamong
generic products should be avoided. This is especially true
in the above-mentioned critical cases and/or in conditions
associated with a strong placebo response [6]. In the
meantime, an harmonization of the various perceptional
characteristics between brand-name and generic products
by pharmaceutical companies—a choice pointing to drug
eﬀectiveness rather than marketing—would maximize the
treatment beneﬁts.
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